Sir,

We thank Dr Norris and Dr McCulloch1 for their interest in our paper2 and for their very informative comments. We fully agree with them on the issues and potential difficulties in designing a randomised controlled trial (RCT) when one of the modalities of treatment (oral propranolol) has a very high ‘success’ rate in published literature. We have highlighted this in our paper under the subheading ‘areas for future research’. We collude with the authors on the need for an RCT to further explore dosage and duration of oral propranolol therapy and to monitor adverse effects.